Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics reached three milestones in recent times and is on its way to product revenue. The biotech company is also making progress with other pipeline programs based on its cutting-edge gene editing technology.

Could CRISPR Therapeutics Stock Help You Become a Millionaire?

Intellia Therapeutics

Intellia Therapeutics is well capitalized, and moving into late-stage clinical trials. CRISPR Therapeutics will be raking in revenue and likely launching another therapy.

Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics

Eli Lilly

Novo Nordisk

CRISPR Therapeutics stock has room to run higher with the biotech's first therapy on the market. Eli Lilly is now the world's biggest drugmaker and has multiple growth drivers.

3 High-Flying Stocks That Could Soar Even More in 2024

Photronics

Zscaler

In the tech space, certain tech stocks stand as front-liners of innovation and strategic brilliance. This article delves into the riveting strategies of three companies that have not merely weathered the storms of their respective industries, but have charted unprecedented courses of triumph.

3 Under-the-Radar Tech Stocks With 250% Growth Potential by 2026

The Food & Drug Administration has approved a second indication for a drug developed using a gene editing process called CRISPR. Casgevy, initially authorised in December for sickle cell disease treatment, the groundbreaking gene therapy is now also sanctioned for treating transfusion-dependent beta-thalassemia.

CRISPR-derived drug gets green light for second indication

Vertex Pharmaceuticals

The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusion-dependent beta thalassemia—marking the second major U.S. regulatory approval for the emerging gene-editing technology.

FDA Approves New CRISPR Gene-Editing Treatment

Crispr won its second gene-editing approval on Tuesday — two months ahead of time. But CRSP stock slipped, and VRTX stock rose minimally.

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock

- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. “We are pleased with the approval of CASGEVY in TDT well ahead of the PDUFA date,” said Samarth Kulkarni, Ph.D.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 12 years and older, Vertex said on Tuesday.

US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder

C3.ai

Investors who are willing to accept risk can be compensated with more upside potential. CRISPR is in the early stages of rolling out gene therapy products that could be very valuable.

These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge

CRISPR passed several major miletones in its quest to bring its first treatment to market. The company has no product revenue, so it's prone to market-driven volatility.

Here's Why CRISPR Therapeutics Stock Rose 54% Last Year

Amgen

argenx

BeiGene

Immunovant Inc

Biotech has been out of favor among investors for over two years. The sector could be on the verge of a trend reversal because of multiple tailwinds.

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

CRISPR Therapeutics recently obtained approval for its gene therapy Casgevy. The therapy could generate close to $4 billion in annual revenue at its peak.

What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?

Amylyx Pharmaceuticals

Boston Scientific

Globus Medical

iRhythm Technologies

Moderna

Teladoc

While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to boil it down to one phrase, it would be permanent relevance.

7 Healthcare Stocks Taking Medicine to the Next Level

Amazon

Chewy

Etsy

Bear markets always have led to bull markets, so there's reason to be optimistic about the future. To prepare for better market times, buy quality growth stocks -- they generally thrive in strong market environments.

My 5 Top Growth Stocks to Buy Hand Over Fist for 2024

Shopify

CRISPR is a leader in gene editing and should land key approvals in the next decade. Shopify has a competitive position in e-commerce and will profit from its expansion.

Want to Get Richer? 2 Stocks to Buy and Hold for 10 Years

Recursion Pharmaceuticals

Toast

Cathie Wood's flagship fund surged 67% last year, well surpassing the S&P 500's performance. The top investor has been buying stocks like hotcakes since the start of the year, adding to some of her favorite positions.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week

Ginkgo Bioworks Holdings

Cathie Wood has loaded up her portfolio with tomorrow's potential healthcare game changers. The superstar investor's commitment to innovation helped her flagship fund jump more than 60% last year.

3 Cathie Wood Stocks to Start Off Your New Year Right

CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

Alphabet

Tesla

Some of these stocks already have delivered big gains, but still have plenty of room to run. Others, thanks to their game-changing technologies, could see their share prices take off at any moment.

5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024

CRISPR Therapeutics recently won regulatory approval for its first product. Casgevy, for blood disorders, has the potential to reach blockbuster status.

Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics

CRISPR Therapeutics is a gene therapy and gene editing company focused on developing gene-based medicines using CRISPR and Cas9 technologies. The company recently gained approval for Casgevy, a cure for sickle-cell disease, marking the first approval of a CRISPR-Cas9 medicine for human use. It has a strong pipeline of drugs in development for various serious illnesses, including blood diseases, cancers, diabetes, and cardiovascular diseases.

CRISPR Therapeutics: Therapies Of The Future Are Almost Here, But Not Yet

Intuitive Surgical

Betting on healthcare's future via healthcare stocks is one of the safest long-term bets you can make. Though changes and advances happen rapidly, healthcare is one industry that is here to stay.

3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition

ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 2:15 p.m. PT in San Francisco.

News for CRISPR Therapeutics Stock (CRSP)